Arbutin

Arbutin

SCHEMBL435261

OC[C@H]1O[C@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TYR

The experimentally established mechanism targets of Arbutin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TYR known ✓ P14679 4/20 1.00
POLB P06746 2/20 0.67
KDM4E B2RXH2 1/20 0.67
GAA P10253 1/20 0.67
MAPT P10636 1/20 0.67
G6PD P11413 1/20 0.67
MAPK1 P28482 1/20 0.67
ADRA1A P35348 1/20 0.67
PTGS2 P35354 1/20 0.67
NPC1 O15118 1/20 0.59
ALDH1A2 O94788 1/20 0.59
ALDH2 P05091 1/20 0.59
ALDH1B1 P30837 1/20 0.59
RAB9A P51151 1/20 0.59
IL2 P60568 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
AKR1B1 P15121 1/20 0.59
DPP4 P27487 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arbutin SCHEMBL13313589 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL4289558 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL15481351 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL285242 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL13956277 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL18175043 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL36352 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL5438300 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL12998301 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT
Arbutin SCHEMBL13054606 1.00 TYR (1.00) TYRPOLBKDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116162640-B Escherichia coli Rosetta strain and application thereof in catalytic synthesis of alpha-arbutin Tichuang Biotechnology (Guangzhou) Co.,Ltd. (CN) 2026-05-26 CN claimed
CN-122075357-A Composition with whitening and anti-wrinkle functions and preparation method and application thereof 2026-05-26 CN claimed
CN-121271827-B Sucrose phosphorylase mutant and application thereof in synthesis of alpha-arbutin 山东三元生物科技股份有限公司 2026-05-22 CN claimed
CN-122031311-A Composition containing ganoderma sinensis fermentation filtrate and application of composition in skin repair and whitening 广东圆度生物科技有限公司 2026-05-15 CN claimed
WO-2025229086-A1 ADHESIVE COSMETIC COMPOUNDS AND USES THEREOF SKINOSIVE (FR) 2025-11-06 WO claimed
US-20250332225-A1 Injectable Neutral pH Collagen-Based Composition For Mesotherapy SHANGHAI QISHENG BIOLOGICAL PREPARATION CO LTD (CN) 2025-10-30 US claimed
CN-120189376-A Whitening essence 开平牵牛生物科技有限公司 2025-06-24 CN claimed
CN-120118734-A Alpha-arbutin enzyme catalytic synthesis equipment and synthesis process thereof 安徽瑞邦生物科技有限公司 2025-06-10 CN claimed
CN-120078694-A Whitening and elastic essence and preparation method thereof 开平牵牛生物科技有限公司 2025-06-03 CN claimed
CN-119709705-B Alpha-glucosidase mutant and application thereof in synthesis of alpha-arbutin 云合(天津)生物技术有限公司 2025-05-30 CN claimed
US-20090263339-A1 AGENT FOR EXTERNAL APPLICATION TO THE SKIN KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKY (JP) 2009-10-22 US claimed
EP-1894558-A1 AGENT FOR EXTERNAL APPLICATION TO THE SKIN Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) 2008-03-05 EP claimed
EP-1289489-B1 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM LTD (CH) 2007-12-05 EP claimed
EP-1859835-A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM Ltd. (CH) 2007-11-28 EP claimed
CN-1635996-A Topical skin preparation containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM LTD (CH) 2005-07-06 CN claimed
US-20030198610-A1 Topical agent for dermatological use DSM IP ASSETS B.V. (NL) 2003-10-23 US claimed
US-20030143251-A1 Skin preparations for external use EZAKI GLICO COMPANY LIMITED (JP) 2003-07-31 US claimed
EP-1289489-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM Ltd. (CH) 2003-03-12 EP claimed
EP-1260211-A1 SKIN PREPARATIONS FOR EXTERNAL USE PENTAPHARM Ltd. (CH) 2002-11-27 EP claimed
WO-2001091715-A2 TOPICAL AGENT FOR DERMATOLOGICAL USE CONTAINING 4-HYDROXYPHENYL-ALPHA-D-GLUCOPYRANOSIDE PENTAPHARM LTD. (CH) 2001-12-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030198610-A1 Topical agent for dermatological use GALE, UGGT1, UGDH TYR 6/4885POLB 2460/4885KDM4E 611/4885
US-20030143251-A1 Skin preparations for external use TYR, GAA, CUTA TYR 1/4885POLB 419/4885KDM4E 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.